QRL-101 demonstrated a dose-dependent, statistically significant decrease in SDTC, a biomarker linked to ALS disease progression and mortality, with effects approximately 50% greater than the previous Kv7 opener ezogabine.
QurAlis' QRL-201, designed to restore STMN2 expression, enters the dose range-finding phase of its Phase 1 ANQUR trial after successful dose escalation.
QurAlis is broadening the clinical application of QRL-101, a selective Kv7.2/7.3 ion channel opener, to include the treatment of epilepsy, a neurological disorder affecting millions worldwide.
Quralis has finished dosing the first group of healthy volunteers in a Phase 1 clinical trial of QRL-101, an oral small molecule therapy for amyotrophic lateral sclerosis (ALS).